TIGIT and cancer: Thus, the presence of functional, TIGIT+ NK cells is critical to the efficacy of anti-TIGIT therapies and adoptive NK cell therapy may further improve the efficacy of anti-TIGIT antibodies by boosting overall T cell immune response against cancer cells in cancer patients frequently lacking the NK cell compartment.